CroíValve today announced the first patient treated with its Duo transcatheter tricuspid coaptation valve system in the TANDEM II study. TANDEM II, an early feasibility study in the U.S., evaluates Duo in the treatment of severe tricuspid regurgitation (TR). Duo works in tandem with the native tricuspid valve to restore valve function. Delivered using percutaneous […]
croivalve
CroíValve raises $16M to support tricuspid coaptation valve
CroíValve announced today that it closed a Series B financing round with proceeds totaling $16 million. The MedTech & Irrus Syndicates led the financing round for the Dublin, Ireland-based tricuspid regurgitation (TR) treatment developer. Current investors Ascentifi, Furthr, Broadview Ventures, Atlantic Bridge University Fund, Enterprise Ireland, Elkstone and SOSV also participated. New investor IAG Capital […]
CroíValve reports positive first-in-human valve repair data
CroíValve today announced favorable patient outcomes in a first-in-human clinical trial of its Duo tricuspid coaptation valve system. Professor Wojciech Wojakowski presented data looking at Duo in the treatment of tricuspid regurgitation (TR) at New York Valves 2024. Duo, a novel, transcatheter coaptation valve, works in tandem with the native tricuspid valve to restore valve […]
CroíValve is set to challenge as tricuspid regurgitation treatment space heats up
With Edwards and Abbott making recent waves in the tricuspid regurgitation (TR) treatment space, CroíValve hopes to pave its own way. Edwards’ Evoque valve became the first transcatheter therapy to receive FDA approval to treat TR in February. This month, Abbott became the second with its TriClip transcatheter edge-to-edge repair (TEER) system picking up an […]
CroíValve wins FDA IDE for tricuspid heart valve
CroíValve announced today that it began an early feasibility study for its Duo tricuspid coaptation valve system. The beginning of the study follows FDA investigational device (IDE) approval. Tandem II, a prospective, multi-center, non-randomized, single-arm study looks at the safety and performance of Duo in patients with severe or greater symptomatic tricuspid regurgitation (TR). Duo […]
CroíValve raises more than $9M in Series A round
CroíValve this week announced that it raised €8 million ($9 million) in a Series A fundraising round to support a feasibility clinical study of its tricuspid valve system. The Dublin-baed company designed its Duo coaptation valve system to treat tricuspid regurgitation (TR), which is a severe heart condition that occurs when the tricuspid valve fails […]
CroíValve adds $4.4m to initiate clinical trials
CroíValve said today that it secured more than $4 million in additional financing as it develops a treatment for tricuspid regurgitation. The funding, which amounts to more than $4.4 million (€4 million) includes more than $2.7 million (€2.5 million) from the European Union under its Horizon 2020 SME Instrument grant. The remaining $1.7 million (€1.5 […]
Tricuspid valve repair device maker CroíValve raises $4m
Early stage tricuspid valve repair device developer CroíValve has raised approximately $3.6 million (EU €3.2 million) in an oversubscribed seed financing round, according to a report from the Irish Times. CroíValve is developing a novel percutaneous solution intended to treat tricuspid regurgitation that seals the central gap between the native valve leaflets to prevent regurgitation, […]
